Combination Therapy of SGLT 2 Inhibitors and GLP 1 Receptor Agonists for Glycaemic Management through Weight Reduction
Abstract
A great deal of anti-diabetic drugs leads to weight gain, which could contribute to obesity and possibly both diabetes and obesity. Glucose-lowering medications that contain sodium-glucose co-transporter 2 (SGLT2) inhibitors work by preventing the kidneys from reabsorbing glucose and sodium, which causes glycosuria and lowers plasma glucose levels. Consequently, its effects include decreases in HbA1c, blood glucose levels, and blood pressure along with decline in body weight and adiposity. Consistently, people on medications that inhibit SGLT2 tend to lose weight, but this weight loss is only modest since opposing regulatory processes work to keep the body's weight constant. This has driven researchers to investigate the use of SGLT2 inhibitors in combination with other drugs that work by reducing appetite, such as glucagon-like peptide 1 receptor agonists (GLP1RAs). In a retrospective study at the Wolver Hampton Diabetes Centre, researchers evaluated the effectiveness of combination therapy using GLP-1 agonists and SGLT-2 inhibitors in the management of diabetes and obesity. Patients on the combined regimen showed statistically significant improvements in clinical measures like body weight reduction, glycated hemoglobin (HbA1c) reduction, lower BMI, and reduced insulin dose. Such combinations, which include SGLT2 inhibitors, are intriguing because of the bodyweight effects and the indications of protection of cardiovascular and renal problems. These results imply that combination therapy using GLP-1 agonists and SGLT-2 inhibitors offers individuals with diabetes and obesity a promising treatment choice
Keywords: Diabetes Mellitus, obesity, SGLT 2 inhibitors, GLP 1 receptor agonist.
Keywords:
Diabetes Mellitus, obesity, SGLT 2 inhibitors, GLP 1 receptor agonistDOI
https://doi.org/10.22270/jddt.v15i1.6914References
1. Egan AM, Dinneen SF. What is diabetes? Medicine (Abingdon). 2019;47(1):1–4. Available from: http://dx.doi.org/10.1016/j.mpmed.2018.10.002.
2. Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol [Internet]. 2020;16(7):377–90. Available from: http://dx.doi.org/10.1038/s41581020-0278-5
3. CLASSIFICATION OF DIABETES MELLITUS 2019. Who.int. Available from: https://iris.who.int/bitstream/handle/10665/325182/9789241515702eng.pdf?sequence=1
4. Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3(1). http://dx.doi.org/10.1038/nrdp.2017.16
5. Schofield J, Ho J, Soran H. Cardiovascular risk in type 1 diabetes mellitus. Diabetes Ther [Internet]. 2019;10(3):773–89. Available from: http://dx.doi.org/10.1007/s13300-019-0612-8
6. Janež A, Guja C, Mitrakou A, Lalic N, Tankova T, Czupryniak L, et al. Insulin therapy in adults with type 1 diabetes mellitus: A narrative review. Diabetes Ther [Internet]. 2020;11(2):387–409. Available from: http://dx.doi.org/10.1007/s13300-019-00743-7
7. Dhakar RC, Maurya SD, Aggarwal S, Kumar G, Tilak VK, Design and evaluation of SRM microspheres of metformin hydrochloride, Pharmacie Globale (IJCP), 2010; 1(1):1-5
8. Olokoba AB, Obateru OA, Olokoba LB. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Med J [Internet]. 2012;27(4):269–73. Available from: http://dx.doi.org/10.5001/omj.2012.68
9. Juan J, Yang H. Prevalence, prevention, and lifestyle intervention of gestational diabetes mellitus in China. Int J Environ Res Public Health. 2020;17(24):9517. Available from: http://dx.doi.org/10.3390/ijerph17249517.
10. Paulo MS, Abdo NM, Bettencourt-Silva R, Al-Rifai RH. Gestational diabetes mellitus in Europe: A systematic review and meta-analysis of prevalence studies. Front Endocrinol (Lausanne) [Internet]. 2021;12. http://dx.doi.org/10.3389/fendo.2021.691033.
11. Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne) [Internet]. 2023;14. Available from: http://dx.doi.org/10.3389/fendo.2023.1161521
12. Cheng L, Wang J, Dai H, Duan Y, An Y, Shi L, et al. Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. Adipocyte [Internet]. 2021;10(1):48–65. http://dx.doi.org/10.1080/21623945.2020.1870060.
13. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23. http://dx.doi.org/10.1038/s41573-02100337-8
14. Day C, Bailey CJ. Obesity in the pathogenesis of type 2 diabetes. Br J Diabetes Vasc Dis [Internet]. 2011;11(2):55–61. Available from: http://dx.doi.org/10.1177/1474651411407418
15. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs [Internet]. 2019;79(3):219–30. Available from: http://dx.doi.org/10.1007/s40265-019-1057-0
16. Pratama, K. ‘Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: A systematic review’, Acta Endocrinologica (Bucharest), 2022;18(2): 216–224. doi: http://dx.doi.org/10.4183/aeb.2022.216 .
17. Brown E, Rajeev SP, Cuthbertson DJ, Wilding JPH. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors. Diabetes Obes Metab [Internet]. 2019;21(S2):9–18. Available from: http://dx.doi.org/10.1111/dom.13650
18. Rizzo, M.R. et al. ‘Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment’, Pharmacological Research, 2022a;176:106062. http://dx.doi.org/10.1016/j.phrs.2022.106062 .
19. Markaki I. et al. ‘Repurposing GLP1 agonists for Neurodegenerative Diseases’, International Review of Neurobiology, 2020a;91–112. http://dx.doi.org/10.1016/bs.irn.2020.02.007 .
20. Ard J, Fitch A, Fruh S, Herman L. Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists. Adv Ther. 2021;38(6):2821–39 Available from: http://dx.doi.org/10.1007/s12325-021-01710-0
21. Skeik, N. et al. (2023) ‘Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A Review’, Vascular Medicine, 28(1), pp. 62–76. doi: http://dx.doi.org/10.1177/1358863x221143811 .
22. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46(101102):101102. Available from: http://dx.doi.org/10.1016/j.molmet.2020.101102
23. Chintam, K. and Chang, A.R. (2021) ‘Strategies to treat obesity in patients with CKD’, American Journal of Kidney Diseases, 77(3), pp. 427–439. doi: http://dx.doi.org/10.1053/j.ajkd.2020.08.016 .
24. Gourdy P, Darmon P, Dievart F, Halimi J-M, Guerci B. Combining glucagonlike peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol [Internet]. 2023;22(1). Available from: http://dx.doi.org/10.1186/s12933-023-01798-4
25. Packer M. Should we be combining GLP-1 receptor agonists and SGLT2 inhibitors in treating diabetes? Am J Med. 2018;131(5):461–3. http://dx.doi.org/10.1016/j.amjmed.2017.11.052
26. Goncalves E, Bell DSH. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk. Diabetes Ther [Internet]. 2018;9(3):919–26. Available from: http://dx.doi.org/10.1007/s13300-018-0420-6
27. Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol [Internet]. 2022;14(6):329–42. http://dx.doi.org/10.4330/wjc.v14.i6.329
28. Sridhar VS, Dubrofsky L, Boulet J, Cherney DZ. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. J Bras Nefrol [Internet]. 2020;42(4):467–77. Available from: http://dx.doi.org/10.1590/2175-8239-jbn-2020-0100
Published



How to Cite
Issue
Section
Copyright (c) 2025 Vinod Kumar , Amulya V B , Manjari Sharma , Saikrupa B V

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).